TB-500: Evidence, Mechanism, Dosing & Legal Status

TB-500 ("Thymosin Beta-4 fragment") is a synthetic, N-acetylated heptapeptide marketed and used as a tissue-repair agent for tendon, muscle, ligament and wound recovery. Its popularity in fitness and recovery circles is large; its proof in humans is essentially zero. This monograph separates the two, and corrects a confusion that undermines most consumer claims: TB-500 is a fragment, not the full thymosin β4 protein.2

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. TB-500 is not an FDA-approved drug; it is sold as a "research chemical not for human use" and is prohibited in sport at all times. Dosing figures are reported strictly as seen in the published literature and grey-market use for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is TB-500 and how does it work?

Thymosin β4 (Tβ4; gene TMSB4X) is a 43-amino-acid, roughly 4.9 kDa β-thymosin expressed in nearly all nucleated cells and present in platelets, plasma and tears.7 TB-500 is not the whole protein: it is the synthetic, N-terminally acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 — the segment historically designated the actin-binding "LKKTET" motif.12 This distinction is load-bearing for the whole monograph: TB-500 differs from full-length Tβ4 in chemistry, pharmacokinetics and regulatory history, and human clinical data generated with the full protein does not transfer to the fragment.24 Many vendors loosely market TB-500 as a "17-amino-acid fragment," but the bona-fide synthetic doping/research agent characterized in the analytical literature is the heptapeptide.2

The core mechanism — all of it preclinical — is actin handling. Tβ4 is the major intracellular G-actin-sequestering peptide: it binds monomeric (globular) actin with roughly micromolar affinity and prevents spontaneous polymerization into filaments, maintaining a mobilizable monomer reservoir that cells draw on to remodel their cytoskeleton during migration.1 Because directed cell migration of keratinocytes, fibroblasts, endothelial cells and myoblasts underlies wound closure and tissue repair, this is the proposed root mechanism for TB-500's regenerative claims. Downstream, in the landmark cardiac study, Tβ4 formed a functional complex with PINCH and integrin-linked kinase (ILK), activating the survival kinase Akt; after coronary-artery ligation in mice it improved early myocyte survival and cardiac function.34 Additional reported pathways include VEGF-mediated angiogenesis, pro-resolution macrophage polarization, MMP-mediated matrix remodeling and TGF-β modulation affecting scar quality.7 As a small acetylated peptide it is not orally bioavailable and is administered parenterally; rigorous human pharmacokinetics for the fragment specifically are not established.23

What is the evidence by indication?

The bottom line up front: there are no published human efficacy RCTs of the TB-500 fragment for any marketed use. Every claim below for the fragment is Grade C (preclinical) unless it concerns full-length Tβ4, where small human trials exist (lower-tier human) — and that molecule is not TB-500.

The corneal indication is the only one with genuine human RCT data, and it is for Tβ4, not TB-500. In the SEER-1 Phase III trial (NCT02600429; multicenter, randomized, double-masked, placebo-controlled) of 0.1% RGN-259 for stage 2-3 neurotrophic keratopathy, complete corneal epithelial healing at Day 29 was 6/10 (60%) versus 1/8 (12.5%) for placebo (p=0.0656) — the primary endpoint was not met, though a Day-43 analysis reached 5/10 versus 0/8 (p=0.0359) and symptom measures improved.8 The trial was small (n=18, terminated early for rare-disease recruitment), and the subsequent SEER-3 Phase 3 trial did not meet its primary endpoint, tempering the picture.910 You can read the SEER-1 trial registration directly at ClinicalTrials.gov. Net: promising but mixed for Tβ4 ophthalmic, and inapplicable to systemic-injection TB-500.

For the marketed athletic claims, the evidence thins further. Preclinically, Tβ4 and its actin-binding fragment promote re-epithelialization, keratinocyte and fibroblast migration, angiogenesis and collagen deposition in rodent wound models.725 Cardiac signals reinforced across mouse, porcine and iPSC-cardiomyocyte work via ILK/Akt.56 But there are no human trials in athletes for tendon, muscle or flexibility outcomes; human use here is anecdotal community report (Grade D) and confounded by polypharmacy such as stacking with BPC-157.27

What doses appear in the literature?

Reported strictly as information, not a protocol or recommendation. There is no validated human dosing protocol for the TB-500 fragment; the figures below circulate in grey-market and community sources and are extrapolated from animal data and practitioner observation, not from controlled human efficacy trials.23 A commonly reported community "loading" phase is roughly 2-2.5 mg subcutaneous twice weekly for four to six weeks, injections spaced three to four days apart, followed by a "maintenance" phase of roughly 2-2.5 mg once weekly or stopping to re-evaluate.23 A reconstitution example circulated is a 10 mg vial plus 2 mL bacteriostatic water giving 5 mg/mL, so a 2-2.5 mg dose is about 0.4-0.5 mL.23 The formal human dosing context is different: Phase 1/2 safety work on full-length Tβ4 used intravenous administration at much higher absolute doses (roughly 42-1,260 mg) — a different molecule and route than community subcutaneous TB-500 use.23 Community protocols favor twice-weekly over daily dosing because the longer biological persistence is attributed to tissue and actin binding rather than plasma residence, but no human PK/PD validation exists for the fragment.23

How safe is TB-500?

Human safety data are anecdotal because there are no controlled human safety trials of the fragment. The most commonly reported effects are injection-site reactions, transient lethargy or fatigue, and a head-rush or flushing sensation; in formal Tβ4 ophthalmic RCTs adverse events were mild and mostly ocular.826 The central safety concern is mechanistic. Tβ4 is a documented driver of tumor angiogenesis and metastasis in preclinical models: in a pivotal JNCI study, overexpression produced roughly a 2.3-fold increase in melanoma cell migration and a 4.4-fold increase in tumor blood-vessel number, and raised metastatic lung nodules to 46.7 versus 10.9 for controls (P<.001).11 Tβ4 is overexpressed in colon, renal, lung, osteosarcoma and hepatoblastoma tissue and promotes EMT and metastasis via ILK/IQGAP1/Rac1 signaling.1213 The same migration and angiogenesis biology that underlies TB-500's repair claims raises a plausible, mechanism-based concern that exogenous administration could accelerate occult or established tumors — unproven in humans but a serious precautionary flag, and the literature is mixed, with some tumor-suppressive contexts.14 Fibrosis and immunogenicity are additional theoretical flags, and the FDA cited immunogenicity and manufacturing-impurity concerns (endotoxin, truncated peptides, diastereomers) when placing the class in Category 2.18 Precautionary exclusion populations include active or prior malignancy, pregnancy and lactation, and pediatric use.

What is the FDA and WADA status in 2026?

TB-500 / thymosin β4 is not FDA-approved for any human indication and is not a lawful dietary-supplement ingredient.20 The regulatory timeline is precise: in September 2023 the FDA placed thymosin β4 / TB-500 — among 19 peptides — into 503A Category 2, barring compounding pharmacies from using it.1518 In April 2026 the FDA removed TB-500 from Category 2 and announced a Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026 to evaluate whether seven peptides — including BPC-157, KPV and TB-500 — should be added to the 503A bulk-substances list, which would, for the first time since 2023, permit patient-specific compounding if approved.1617 As of mid-2026 the outcome is pending; the current status is "not Category-2-barred, but not affirmatively listed or permitted either." Outside any compounding pathway, TB-500 is sold as a research chemical not for human use, typically without established quality controls.20

For athletes the picture is unambiguous. TB-500 is prohibited at all times under WADA S2.3 (Growth Factors and Growth Factor Modulators), explicitly named as "Thymosin-β4 and its derivatives, e.g. TB-500"; it is also captured by S0 and is a non-Specified Substance, the strictest sanction tier.19 It was added as an explicit S2.3 example in the 2018 list; sanctions run two to four years, and a real case produced a four-year ban for combined BPC-157 and TB-500 use.2120 The U.S. Department of Defense has adopted the WADA categories, making it prohibited for testable military personnel, and it is a regulated or prescription medicine in jurisdictions such as Australia and New Zealand.22

Bottom line. TB-500 is a mechanistically interesting, preclinically supported tissue-repair fragment with essentially zero human efficacy evidence for the indications it is marketed for — graded C overall, drifting to D where claims rest on athlete anecdote. Three caveats dominate: it is the heptapeptide fragment, not full-length Tβ4; no human RCT of the fragment exists for muscle, tendon, cardiac or wound repair; and a mechanism-based tumor/angiogenesis safety concern is unresolved. Regulatory facts here are current as of June 2026; the July 23-24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.